Is Alpha Teknova, Inc. overvalued or undervalued?

As of 11 August 2021, the valuation grade for Alpha Teknova, Inc. moved from expensive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, particularly with a Price to Book Value of 4.03 and an EV to Sales ratio of 7.99, both of which suggest a premium valuation relative to its financial performance. Additionally, the negative EV to EBITDA of -18.40 further underscores the challenges the company faces in generating earnings.
In comparison to peers, CytomX Therapeutics, Inc. is categorized as very attractive with a P/E ratio of 7.49, while both Capricor Therapeutics, Inc. and Ocuphire Pharma, Inc. are also deemed risky with P/E ratios of -4.15 and -2.46, respectively. This peer comparison highlights that Alpha Teknova is not only struggling with profitability but is also lagging behind its competitors in terms of valuation metrics. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -44.43% compared to the index's 12.22%, reinforcing the notion that it may be overvalued in the current market context.